Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin L Ricker

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|May 10, 2014
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanibHao Xiong, Yi-Lin Chiu, Justin L Ricker, et al.
Cancer Letters|February 10, 2006
Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell linesEric R Snyder, Justin L Ricker, Zhong Chen, et al.
Head & Neck|April 4, 2007
Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neckClint T Allen, Justin L Ricker, Zhong Chen, et al.
Kidney International|October 10, 2002
Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney diseaseVincent H Gattone, Justin L Ricker, Chad M Trambaugh, et al.
Journal of the American Society of Nephrology : JASN|September 27, 2000
Development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk miceJustin L Ricker, Vincent H Gattone, James P Calvet, et al.
Clinical Therapeutics|October 8, 2013
Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinomaYi-Lin Chiu, Dawn M Carlson, Rajendra S Pradhan, et al.
Kidney International|February 14, 2002
c-myc antisense oligonucleotide treatment ameliorates murine ARPKDJustin L Ricker, John E Mata, Patrick L Iversen, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2013
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumorsYi-Lin Chiu, Patricia Lorusso, Balakrishna Hosmane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinomaJustin L Ricker, Zhong Chen, Xin Ping Yang, et al.
Investigational New Drugs|April 22, 2008
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancerJohan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|May 10, 2014
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanibHao Xiong, Yi-Lin Chiu, Justin L Ricker, et al.
Cancer Letters|February 10, 2006
Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell linesEric R Snyder, Justin L Ricker, Zhong Chen, et al.
Head & Neck|April 4, 2007
Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neckClint T Allen, Justin L Ricker, Zhong Chen, et al.
Kidney International|October 10, 2002
Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney diseaseVincent H Gattone, Justin L Ricker, Chad M Trambaugh, et al.
Journal of the American Society of Nephrology : JASN|September 27, 2000
Development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk miceJustin L Ricker, Vincent H Gattone, James P Calvet, et al.
Clinical Therapeutics|October 8, 2013
Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinomaYi-Lin Chiu, Dawn M Carlson, Rajendra S Pradhan, et al.
Kidney International|February 14, 2002
c-myc antisense oligonucleotide treatment ameliorates murine ARPKDJustin L Ricker, John E Mata, Patrick L Iversen, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2013
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumorsYi-Lin Chiu, Patricia Lorusso, Balakrishna Hosmane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinomaJustin L Ricker, Zhong Chen, Xin Ping Yang, et al.
Investigational New Drugs|April 22, 2008
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancerJohan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, et al.
Pageof 3